Moteur de recherche d’entreprises européennes
Financement de l’UE (6 256 759 €) : ARN chimiquement modifiés assistés par matrice imprimée en 3D Thérapie régénérative osseuse pour les patients traumatisés et ostéoporotiques Hor27/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
ARN chimiquement modifiés assistés par matrice imprimée en 3D Thérapie régénérative osseuse pour les patients traumatisés et ostéoporotiques
Due to life style changes and ageing of our industrialized nations, bone traumatic injuries and osteoporosis induced fragile fracture are an enormous medical and socio-economic challenge. State-of-the-art therapies have failed until now in keeping their promises of reliable bone regenerative solutions. The cmRNAbone project aim to create a novel bone regenerative therapeutic approach based on combination of chemically modified RNAs (cmRNAs)-vectors embedded in a 3D-printed guiding biomaterial ink tailored to patients need. To achieve our goal, sema3a, vegf, pdgf-bb and bmp7 cmRNAs targeting neurogenesis, vasculogenesis and osteogenesis will be synthesized, vectors based on lipids and polysaccharide nanocapsules for the delivery of cmRNAs will be developed. A functional Hyaluronan-Calcium Phosphate biomaterial ink that 1) can be loaded with cmRNAs-vectors and release them, 2) having intrinsic osteoinductivity and presenting laminin-derived peptides for guiding sensory neurons and endothelial cells ingrowth, and 3) being amenable to an extrusion-based 3D-bioprinting process will be formulated in conjunction to a 3D-printer for fabrication of patient specific regenerative solution. In the following step, a large effort will focus on deciphering regenerative mechanisms and optimizing dosage and ratio of cmRNAs, loading of cmRNAs-vectors in the ink, 3D-printing, etc, to demonstrate regenerative capabilities in vitro and in vivo. Selected candidate formulations will be taken to clinically relevant preclinical proof of concepts. Finally, an overreaching effort on preparing a 1st in human trial will be taken, consisting on partners facilities auditing and clinical experts group support, etc, to ensure that GMP-like production for all regenerative tools, and regulatory and commercial strategies are realized.
| ETHRIS GmbH | 490 526 € |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | 457 500 € |
| Fundacion Cidetec | 443 500 € |
| Fundacion Idonial | 310 500 € |
| Institut National de la Sante et de la Recherche Medicale | 0,00 € |
| Institut Polytechnique de Bordeaux | 0,00 € |
| KUROS BIOSCIENCES B.V. | 435 139 € |
| OZ Biosciences SAS | 447 750 € |
| Qbex GmbH | 184 216 € |
| UNIVERSITAT BASEL | 659 570 € |
| UNIVERSITATSSPITAL BASEL | 0,00 € |
| Universite de Bordeaux | 1 117 559 € |
| UNIVERSITEIT MAASTRICHT | 999 749 € |
| АО-FORSCHUNGSINSTITUT DAVOS | 710 750 € |
https://cordis.europa.eu/project/id/874790
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.